X

Drug Profile

NP MP1

Alternative Names: NP-MP1

Latest Information Update: 12 Jan 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NanoPhoria Bioscience
Class Heart failure therapies; Peptides; Peptidomimetics
Mechanism of Action L-type calcium channel modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Chronic heart failure

Most Recent Events

02 Jan 2024 Preclinical trials in Chronic heart failure in Italy (Inhalation) prior to January 2024 (NanoPhoria Bioscience pipeline, January 2024)
02 Jan 2024 Pharmacodynamics and adverse events data from the preclinical studies in Chronic heart failure released by NanoPhoria Bioscience
02 Jan 2024 NanoPhoria Bioscience plans a clinical trial for Chronic heart failure

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com